Literature DB >> 18628739

Intermittent androgen blockade should be regarded as standard therapy in prostate cancer.

Bostjan Seruga1, Ian F Tannock.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18628739     DOI: 10.1038/ncponc1180

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


× No keyword cloud information.
  23 in total

Review 1.  Metronomic chemotherapy: new rationale for new directions.

Authors:  Eddy Pasquier; Maria Kavallaris; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2010-06-08       Impact factor: 66.675

Review 2.  Drug rechallenge and treatment beyond progression--implications for drug resistance.

Authors:  Elizabeth A Kuczynski; Daniel J Sargent; Axel Grothey; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2013-09-03       Impact factor: 66.675

Review 3.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

Authors:  William P Harris; Elahe A Mostaghel; Peter S Nelson; Bruce Montgomery
Journal:  Nat Clin Pract Urol       Date:  2009-02

4.  Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer'.

Authors:  Nicolas André; Eddy Pasquier
Journal:  Nat Clin Pract Oncol       Date:  2009-02

Review 5.  Tumor metastasis: moving new biological insights into the clinic.

Authors:  Liling Wan; Klaus Pantel; Yibin Kang
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 6.  [Uro-oncology--update 2009].

Authors:  T Otto
Journal:  Urologe A       Date:  2009-09       Impact factor: 0.639

Review 7.  Testosterone Therapy Among Prostate Cancer Survivors.

Authors:  Taylor M Nguyen; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2016-07-27

Review 8.  Pharmacotherapeutic management of locally advanced prostate cancer: current status.

Authors:  Jarad M Martin; Stephane Supiot; Dominik R Berthold
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

9.  Intermittent androgen deprivation therapy: redefining the standard of care?

Authors:  Neal D Shore; E David Crawford
Journal:  Rev Urol       Date:  2010

Review 10.  An update on androgen deprivation therapy for prostate cancer.

Authors:  Nima Sharifi; James L Gulley; William L Dahut
Journal:  Endocr Relat Cancer       Date:  2010-10-29       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.